 WALTHAM, Mass., Aug. 05, 2020 GLOBE NEWSWIRE -- Entasis Therapeutics Holdings Inc. NASDAQ: ETTX, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11th at 11:30am ET and at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12th at 9:00am ET.2020 Wedbush PacGrow Healthcare Virtual Conference: Date:Tuesday, August 11th, 2020 Location: Time:11:30 AM ET Canaccord Genuity 40th Annual Growth Conference: Date:Wednesday, August 12th, 2020 Time:9:00 AM ET A replay of the Wedbush presentation will be available on the Companys website for 90 days following the event. Additionally, Dr. Perros and Dr. Michael Gutch, Chief Financial and Chief Business Officer, will hold 1-on-1 virtual investor meetings at the conferences. Investors attending the conferences virtually who are interested in meeting with Company management should contact their Wedbush and Canaccord representatives.About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam targeting Acinetobacter baumannii infections, zoliflodacin targeting Neisseria gonorrhoeae infections, ETX0282CPDP targeting Enterobacteriaceae infections and ETX0462 targeting Pseudomonas infections. For more information, visit Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions as well as other words or expressions referencing future events, conditions or circumstances are intended to identify forward-looking statements. These forward-looking statements are based on Entasis expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis control. These and other risks and uncertainties are described more fully in the Entasis filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.Entasis Company Contact Kyle Dow Entasis Therapeutics 781 810-0114 Relations Contacts James Salierno The Ruth Group 646 536-7028 Contact Kirsten Thomas The Ruth Group 508 280-6592 